Sodium phosphate dibasic dodecahydrate CAS:10039-32-4 Basic information
|Product Name:||Sodium phosphate dibasic dodecahydrate|
|Synonyms:||di-Sodium hydrogen phosphate dodecahydrate for analysis EMSURE ISO,Reag. Ph Eur;SODIUM PHOSPHATE DIBASIC DODECAHYDRA;Dibasic Sodium Phosphate Dodecahydrate;Sodium Phosphate Dibasic Dodecahydrate, Meets analytical specification of Ph.Eur.BP;DI-SODIUM HYDRO|
|Product Categories:||Food Additives|
Sodium phosphate dibasic dodecahydrate CAS:10039-32-4 Chemical Properties
|Melting point:||35 °C|
|storage temp.:||Store at +15°C to +25°C.|
|Water Solubility:||218 g/L (20 ºC)|
|solubility:||H2O: 0.1 M at 20 °C, clear, colorless|
|λmax:||λ: 260 nm Amax: 0.01λ: 280 nm Amax: 0.01|
|CAS DataBase Reference:||10039-32-4(CAS DataBase Reference)|
|EPA Substance Registry System:||Disodium phosphate dodecahydrate (10039-32-4)|
Content(On the base of dry basis)≥%
Heave metals(as pb) ≤%
Loss on drying(Na2HPO4.2H2O)≤%
Water Insolubles ≤%
|Sodium phosphate dibasic dodecahydrate Usage And Synthesis|
|Chemical Properties||white crystals|
|Chemical Properties||The USP 32 states that dibasic sodium phosphate is dried or contains, 1, 2, 7, or 12 molecules of water of hydration. Anhydrous dibasic sodium phosphate occurs as a white powder. The dihydrate occurs as white or almost white, odorless crystals.|
The heptahydrate occurs as colorless crystals or as a white granular or caked salt that effloresces in warm, dry air. The dodecahydrate occurs as strongly efflorescent, colorless or transparent crystals.
|Production Methods||Either bone phosphate (bone ash), obtained by heating bones to whiteness, or the mineral phosphorite is used as a source of tribasic calcium phosphate, which is the starting material in the industrial production of dibasic sodium phosphate.|
Tribasic calcium phosphate is finely ground and digested with sulfuric acid. This mixture is then leached with hot water and neutralized with sodium carbonate, and dibasic sodium phosphate is crystallized from the filtrate.
|Definition||ChEBI: A hydrate that is the dodecahydrate form of disodium hydrogenphosphate|
|Pharmaceutical Applications||Dibasic sodium phosphate is used in a wide variety of pharmaceutical formulations as a buffering agent and as a sequestering agent. Therapeutically, dibasic sodium phosphate is used as a mild laxative and in the treatment of hypophosphatemia.|
Dibasic sodium phosphate is also used in food products; for example as an emulsifier in processed cheese.
|Safety||Dibasic sodium phosphate is widely used as an excipient in parenteral, oral, and topical pharmaceutical formulations. Phosphate occurs extensively in the body and is involved in many physiological processes since it is the principal anion of intracellular fluid. Most foods contain adequate amounts of phosphate, making hypophosphatemia (phosphate deficiency) virtually unknown except for certain disease states or in patients receiving total parenteral nutrition. Treatment is usually by the oral administration of up to 100 mmol of phosphate daily.|
Approximately two-thirds of ingested phosphate is absorbed from the gastrointestinal tract, virtually all of it being excreted in the urine, and the remainder is excreted in the feces.
Excessive administration of phosphate, particularly intravenously, rectally, or in patients with renal failure, can cause hyperphosphatemia that may lead to hypocalcemia or other severe electrolyte imbalances. Adverse effects occur less frequently following oral consumption, although phosphates act as mild saline laxatives when administered orally or rectally. Consequently, gastrointestinal disturbances including diarrhea, nausea, and vomiting may occur following the use of dibasic sodium phosphate as an excipient in oral formulations. However, the level of dibasic sodium phosphate used as an excipient in a pharmaceutical formulation is not usually associated with adverse effects.
LD50 (rat, oral): 17 g/kg
|storage||The anhydrous form of dibasic sodium phosphate is hygroscopic. When heated to 40℃, the dodecahydrate fuses; at 100℃ it loses its water of crystallization; and at a dull-red heat (about 240℃) it is converted into the pyrophosphate, Na4P2O7. Aqueous solutions of dibasic sodium phosphate are stable and may be sterilized by autoclaving.|
The bulk material should be stored in an airtight container, in a cool, dry place.
|Incompatibilities||Dibasic sodium phosphate is incompatible with alkaloids, antipyrine, chloral hydrate, lead acetate, pyrogallol, resorcinol and calcium gluconate, and ciprofloxacin. Interaction between calcium and phosphate, leading to the formation of insoluble calcium-phosphate precipitates, is possible in parenteral admixtures.|
|Regulatory Status||GRAS listed. Accepted in Europe for use as a food additive. Included in the FDA Inactive Ingredients Database (injections; infusions; nasal, ophthalmic, oral, otic, topical, and vaginal preparations). Included in nonparenteral and parenteral medicines licensed in the UK. Included in the Canadian List of Acceptable Non-medicinal Ingredients.|